SCHEMBL21588115

SCHEMBL21588115

COc1cc(C2Oc3cc(C4Oc5cc(O)cc(OC)c5CC4O)cc(O)c3OC2CO)ccc1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.53
▸ CYP2C9 P11712 4/20 0.53
▸ CYP3A4 P08684 4/20 0.53
▸ ALOX15 P16050 4/20 0.53
▸ ALDH1A1 P00352 4/20 0.53
▸ MAPT P10636 4/20 0.53
▸ HSD17B10 Q99714 4/20 0.53
▸ GAA P10253 4/20 0.53
▸ SLCO1B3 Q9NPD5 3/20 0.53
▸ SLCO1B1 Q9Y6L6 3/20 0.53
▸ HPGD P15428 3/20 0.53
▸ MEN1 O00255 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ SLCO2B1 O94956 2/20 0.53
▸ F2 P00734 2/20 0.53
▸ TSHR P16473 2/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ ALOX12 P18054 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ PLAU P00749 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21588131 0.95 KDM4E (0.57) KDM4ECYP2C9CYP3A4ALOX15ALDH1A1
SCHEMBL21588113 0.94 CYP2C9 (0.49) KDM4ECYP2C9CYP3A4ALOX15ALDH1A1
SCHEMBL21588098 0.92 CYP3A4 (0.58) KDM4ECYP2C9CYP3A4ALOX15ALDH1A1
SCHEMBL21588158 0.90 CYP3A4 (0.51) KDM4ECYP2C9CYP3A4ALOX15ALDH1A1
SCHEMBL26481102 0.89 DPP4 (0.49) KDM4ECYP2C9CYP3A4ALOX15ALDH1A1
SCHEMBL21588101 0.87 DPP4 (0.46) KDM4ECYP2C9CYP3A4ALOX15ALDH1A1
SCHEMBL21588057 0.87 KDM4E (0.53) KDM4ECYP2C9CYP3A4ALOX15ALDH1A1
SCHEMBL862110 0.86 BACE1 (0.62) KDM4ECYP3A4ALOX15ALDH1A1MAPT
SCHEMBL1974812 0.86 BACE1 (0.62) KDM4ECYP3A4ALOX15ALDH1A1MAPT
SCHEMBL21588060 0.85 KDM4E (0.52) KDM4ECYP2C9CYP3A4ALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643405-B2 Compound for treatment or prevention of liver diseases JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-05-09 — — US claimed
CN-110183431-B Compound for treating or preventing liver diseases 江苏新元素医药科技有限公司 2023-04-11 — — CN claimed
US-20210246126-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2021-08-12 — — US claimed
EP-3805216-A1 COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) 2021-04-14 — — EP claimed
US-11643405-B2 Compound for treatment or prevention of liver diseases JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-05-09 — — US disclosed
US-11643405-B2 Compound for treatment or prevention of liver diseases JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-05-09 — — US disclosed
US-11643405-B2 Compound for treatment or prevention of liver diseases JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-05-09 — — US disclosed
CN-110183431-B Compound for treating or preventing liver diseases 江苏新元素医药科技有限公司 2023-04-11 — — CN disclosed
US-20210246126-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2021-08-12 — — US disclosed
US-20210246126-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2021-08-12 — — US disclosed
EP-3805216-A1 COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) 2021-04-14 — — EP disclosed
EP-3805216-A1 COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) 2021-04-14 — — EP disclosed
WO-2019233440-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES 江苏新元素医药科技有限公司 (CN) 2019-12-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246126-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES SLC10A1, GYS2, CPT1A KDM4E 4649/4885CYP2C9 176/4885CYP3A4 187/4885
US-11643405-B2 Compound for treatment or prevention of liver diseases SLC10A1, GYS2, CPT1A KDM4E 4649/4885CYP2C9 176/4885CYP3A4 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback